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Background. Drug overdose is an important, yet an inade-
quately understood, public health problem. Global attention to
unintentional drug overdose has been limited by comparison
with the scope of the problem. There has been a substantial
increase in drug overdose incidence and prevalence in several
countries worldwide over the past decade, contributing to both
increased costs andmortality.
Objectives. The aim of this study was to systematically
synthesize the peer-reviewed literature to document the global
epidemiological profileofunintentionaldrugoverdoses and the
prevalence, time trends, mortality rates, and correlates of drug
overdoses. We searched different combinations of Medical
Subject Headings (MeSH) terms in PubMed for articles pub-
lished from1980until July 2013, andweorganized these results
in tabular spreadsheets and compared them. We restricted the
search to English-language articles that deal with unintentional
overdose, focusingon1ormoreof the followingkey constructs:
prevalence, timetrends,mortalityrates,andcorrelates.Theterm
“overdose” as a MeSH major topic yielded 1076 publications.
In addition, we searched the following combinations of non-
majorMeSH terms: “street drugs” and “overdose” yielded 180,
“death” and “overdose” yielded 114, and “poisoning” and
“drug users” yielded 17. There was some overlap among the
searches. Based on the search and inclusion and exclusion
criteria,weselecteda totalof 169 relevantarticles for thisarticle
based on a close review of abstracts.
Results. We found wide variability in lifetime prevalence
of experiencing a nonfatal overdose or witnessing an over-
dose, and inmortality rates attributable tooverdose. Lifetime
prevalence of witnessed overdose among drug users (n = 17
samples) ranged from 50% to 96%, with a mean of 73.3%,
amedian of 70%, and a standard deviation of 14.1%. Lifetime
prevalence of drug users personally experiencing a nonfatal
overdose (n = 27 samples), ranged from 16.6% to 68.0% with
a mean of 45.4%, a median of 47%, and a standard deviation
of14.4%.Population-basedcrudeoverdosemortality rates(n=28
samples) ranged from0.04 to 46.6 per 100000person-years. This
rangeis likelyattributable to thediversity inregions, timeperiods,
and samples. Most studies on longitudinal trends of overdose
death rates or overdose-related hospitalization rates showed
increases in overdose death rates and in overdose-related
hospitalizationratesacrosstime,whichhaveledtopeaksinthese
rates at the present time. An overall trend of increasing deaths
from prescription opioid use and decreasing deaths from illicit
drug use in thepast several years has been noted acrossmost of
the literature. With the increase in prescription opioid overdose
deaths, drug overdose is not just an urban problem: rural areas
have seen an important increase in overdose deaths. Lastly,
cocaine, prescription opioids, and heroin are the drugs most
commonly associatedwith unintentional drug overdosesworld-
wide and the demographic and psychiatric correlates associated
with unintentional drug overdoses are similar globally.
Conclusions.Thereisaneedtoinvest inresearchtounderstand
the distinct determinants of prescription drug overdose world-
wide. Several other countries need to collect in a systematic and
continuous fashion such data on sales of prescription opioids
and other prescription drugs, nonmedical use of prescription
drugs, and hospitalization secondary to overdoses on pre-
scription drugs. The sparse evidence on the environmental
determinantsofoverdosesuggestsaneed for research thatwill
inform the types of environmental interventions we can use
to prevent drug overdose. Methodological issues for future
studies include enhancing data collection methods on un-
intentional fatal and nonfatal overdoses, and collecting more
detailedinformationondrugusehistory,sourceofdruguse(for
prescription drugs), and demographic and psychiatric history
characteristics of the individual who overdosed. (Am J Public
Health. 2015;105:e29–e49. doi:10.2105/AJPH.2015.302843)
PLAIN-LANGUAGE SUMMARY:
Drug overdose is an important, yet
inadequately understood, public
health problem. The aim of this
study was to systematically summa-
rize the peer-reviewed literature to
document the global epidemiological
profile of unintentional drug over-
doses, and the prevalence, time
trends, mortality rates, and correlates
of drug overdoses from 1980 until
2013. We found wide variability in
prevalence mortality rates attribut-
able to overdose. Most studies on
longitudinal trends of overdose
deaths or overdose-related hospitali-
zations showed increases across time.
An overall trend of increasing deaths
from prescription opioid use and
decreasing deaths from illicit drug
use in the past several years has been
noted across most of the literature.
With the increase in prescription
opioid overdose deaths, drug over-
dose is not just an urban problem:
rural areas have seen an important
increase in overdose deaths. Lastly,
cocaine, prescription opioids, and
heroin are the drugsmost commonly
associated with unintentional drug
overdoses worldwide and the de-
mographic and psychiatric correlates
associated with unintentional drug
overdoses are similar globally. Fu-
ture studies need to collect more
detailed information on drug use
history, source of drug use (for pre-
scription drugs), and demographic
and psychiatric history characteristics
of the individual who overdosed.
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Worldwide attention to unin-
tentional drug overdose has been
limited by comparison with the
scope of the problem.1 There has
been a substantial increase in drug
overdose mortality in several
countries worldwide over the past
decade. The mortality rate from
drug overdoses tripled in the
United States between 1990 and
2006.2 In the United States, un-
intentional overdose deaths
among adults aged 25 to 64 years
exceeded motor vehicle crash
deaths and suicides as a leading
cause of injury death from 2008
onward.3 Likewise, unintentional
overdose deaths outnumbered
motor vehicle crash deaths in
Australia in 2011.4 In Europe,
rates have been stable since 2005,
but most European countries also
have high overdose rates. For
example, overdose rates of more
than 20 deaths per million are
found in 14 of 30 European
countries, and rates of more
than 40 deaths per million in 7
countries.5
Until recently, drug overdoses
were seen as a substance abuse or
law enforcement issue and not as
a public health problem.1 How-
ever, partly because of the in-
creasing involvement of legal
prescription drugs such as pre-
scription opioids in drug over-
doses, public health professionals
have become more interested in
the topic and in diminishing the
societal burden posed by unin-
tentional overdoses.1
Although drug overdose deaths
attract much public attention,1,6---8
there are substantial conse-
quences of nonfatal overdose, in-
cluding cardiac and muscular
problems, cognitive impairment,
renal failure, hearing loss, and in-
juries sustained during over-
dose.9,10 Health care costs associ-
ated with overdose treatment are
also substantial. From 1999 to
2008, hospitalization rates for
overdoses in the United States in-
creased by 55%, costing about
$737 million in 2008.11There are
little data available on drug over-
dose hospitalization costs in
countries other than the United
States.
Drug overdose can be defined
as happening when
someone . . . collapses, has blue
skin, has convulsions, has diffi-
culty breathing, loses conscious-
ness, cannot be woken up, has
a heart attack or dies while using
drugs.12(p704)
This definition has been used
widely across the literature.13---16
Unintentional drug overdoses are
unique among causes of morbidity
and mortality in 2 respects. First,
unintentional overdose deaths are
rarely instantaneous and drug
users rarely overdose alone. As
such, for the most part, overdose
deaths are avoidable deaths. For
example, those who witness an
overdose episode can call for help
and apply first aid measures.16
Opioid overdoses are preventable
through the administration of nal-
oxone, which can reverse the ef-
fect of opioids and can revive the
individual.16---18 Second, drug
overdoses are inevitably and in-
extricably linked to the surround-
ing environment, particularly in
the centrality of drug availability
as a necessary (but insufficient)
determinant of overdose.19---23
Considering these observations
that overdose is preventable and
linked to surrounding environ-
ment, drug overdoses should be of
concern to public health, both
from the point of view of under-
standing their determinants and
from the point of view of encour-
aging interventions to mitigate
their consequences.
A systematic review of the
drug overdose literature can help
clarify what we know about
unintentional drug overdoses and
areas in which we have gaps in
scholarship. Although reviews have
been written about overdoses
caused by particular types of drugs
(e.g., prescription opioids, heroin,
methadone),24--27 in certain places
(e.g., Utah),28 on suicidal versus
accidental overdose,29 or on over-
doses among recently released
prisoners,30 we are not aware of
any global review of unintentional
drug overdoses with the goal of
synthesizing the prevalence, time
trends, mortality rates, and corre-
lates of drug overdose worldwide.
METHODS
The potential scope of literature
that may be considered of interest
to the topic is vast. We conducted
a systematic review of publications
available in the US National Li-
brary of Medicine’s PubMed elec-
tronic database31 in July 2013 by
using different combinations of
Medical Subject Headings (MeSH)
search terms. We restricted the
search to English-language articles
published between 1980 and July
2013 that deal with unintentional
overdose, focusing on1or more of
the following key constructs:
prevalence, time trends, mortality
rates, and correlates. The term
“overdose” as a MeSH Major
Topic yielded 1076 publications.
In addition, we searched the fol-
lowing combinations of nonmajor
MeSH terms: “street drugs” and
“overdose” yielded 180, “death”
and “overdose” yielded 114, and
“poisoning” and “drug users”
yielded 17. There was some over-
lap among the searches. We did
not use “unintentional” as a search
term so as not to leave out studies
that dealt with both intentional
and accidental overdoses. There
were no limitations in this original
search on type of sample, or loca-
tion or geography, but we
excluded studies dealing with
children, because, although this
group is important, we aimed to
focus only on studies that reported
on unintentional drug overdoses
among adults. We included com-
mentaries because of their poten-
tial to shed light on potential in-
terventions or trends. In addition,
we reviewed reference lists of
chosen articles to select additional
studies or commentaries.
With these search and inclusion
and exclusion criteria, we selected
a total of 169 relevant articles for
this study through a close review
of abstracts (Figure 1). We were
interested in articles that reported
1. population-based prevalence
measures (46 articles; re-
ported in Table 1),
2. studies that reported per-
centage of changes over time
in trends of overdose (34
articles; Table 2),
3. mortality rates (53 articles;
Table 3), and
4. correlates of overdose (sum-
marized in the Results
section, but not included in
tables because of the lack of
common quantitative mea-
sures to record these topics).
RESULTS
Table 1 shows prevalence of
overdose found in relevant arti-
cles, organized by type of drug,
sample, and type of prevalence
(witnessed vs experienced, fatal vs
nonfatal, and time point). Lifetime
prevalence of witnessed overdose
among drug users (n = 17 samples
from 18 articles) ranged from
50% to 96%,15---17,32,33,37,39,40,
43---45,53,54,57---60,64 with a mean
of 73.3%, a median of 70%, and
a standard deviation of 14.1%.
Although samples differed in de-
mographics, length of drug use,
and type of drug involved (e.g.,
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prescription opioids, cocaine), the
lifetime prevalence of witnessing
an overdose did not differ greatly
between studies conducted in dif-
ferent settings and countries.
Two studies reported lifetime
prevalence of witnessing a fatal
overdose specifically: 1 found that
4 of 24 drug users attending
a general medical practice in
inner-city Dublin, Ireland, in 1998
to 1999 had witnessed a fatal
overdose40; the other reported
a 15% prevalence among 763
injection drug users from 16 dif-
ferent cities of the Russian Feder-
ation.59 Two studies reported
past-year prevalence of witnessed
fatal or nonfatal overdose: 50%
among 973 users aged younger
than 30 years who had injected
drugs in the previous month in 4
neighborhoods of San Francisco,
California,58 and 58% of 212
users in Dorset, United Kingdom,
who had injected in the previous 2
months.62 One study of drug users
aged 18 years or older in New
York City (n = 1184) reported
past-6-month prevalence of wit-
nessing overdose at 35.2%16 and
2 samples of injection drug users
reported past-3-month prevalence
of witnessing overdose at 48.5%
and 50%.32,55
Lifetime prevalence of drug
users personally experiencing
a nonfatal overdose had a con-
siderably wider range across
studies (n = 29 samples), varying
from 16.6% to 68.0%,9,13---16,32,
37-44,46---48,50,53,56,58-61,63,64,67---69
with a mean of 45.4%, a median
of 47%, and a standard deviation
of 14.4%. Past-year prevalence of
drug users personally experienc-
ing a nonfatal overdose (n =14
samples) ranged from 4.0% to
38.0%,9,35,36,42,46---50,52,58,62,63,67
with a mean of18.8%, a median of
16.8%, and a standard deviation
of 8.9%. Past-6-month preva-
lence of drug users personally
experiencing a nonfatal overdose
ranged from 6.7% to 33% (n = 7
samples),19,34,51,61,65,66,70 with
a mean of 18.5%, a median of
17%, and a standard deviation of
10.4%. Two studies reported
past-3-month prevalence of
overdose: one found that 11.9%
of drug users had overdosed out
of 644 users younger than 30
years in San Francisco who had
injected in the past 30 days56
and the other found a prevalence
of 15.2% among injection drug
users, most of whom were
homeless or in temporary hous-
ing, in Los Angeles, California,
in 2006.55
Trends
We reviewed articles for overall
longitudinal trends of overdose
death rates or overdose-related
hospitalization rates (Table 2).
Rates of increase for overdose
deaths in population samples
caused by any substance ranged
from a 5.3% average increase per
year in the United States from
1979 to 1990 to a 400% increase
in both Glasgow, Scotland, be-
tween 1991 and 1992, and Ver-
mont between 2001 and
2006.6,71---73,75---85
Between 1974 and 1992 in
England and Wales, there was
a 1186% increase in lethal self-
poisonings from heroin alone.101
In the same location between
2007 and 2008, there was an 8%
increase in heroin or morphine
deaths among women, and a 20%
increase in cocaine deaths among
women.85 There was a 21.4% de-
crease in illicit drug overdose
deaths in Florida between 2003
and 2009,82 and a 43% to 85%
decrease among all drug-related
deaths in Australia in 2001.74 In
the Australian study, the reduction
is believed to have been driven
mainly by a reduction in heroin
supply. A 34% decrease in illicit
drug overdose deaths was seen in
the city of Chicago, Illinois, from
2000 to 2003.95 One study re-
ported a 55% increase in hospi-
talization rates for drug overdoses
on all substances among a nation-
wide sample in the United States
from 1999 to 2008.11
An overall trend of increasing
deaths from prescription opioid use
and decreasing deaths from illicit
drug use in the past several years
has been noted across most of the
literature.80--82,89,90,96,97,99,100
With the exception of Australia,
which experienced a 60% decrease
in opioid deaths between1990 and
2001,91 most studies in Table 2
reported increased rates of deaths
from opioids.2,6,80--82,87,90,92,100
For example, there was a 467.7%
increase reported in methadone
1387 total publications 
found from original searches 
1044 publications removed 
after title review because of  
duplicates and nonrelevant 
articles
343 relevant publications  
after title review
114 publications included   
for mortality, prevalence, 
or trends tables
55 additional articles 
drawn upon for 
discussion, correlate 
results, or reference 
174 nonrelevant articles not 
included in final article after 
closer abstract review
FIGURE 1—Flowchart of selection of peer-reviewed articles to document the worldwide epidemiological
profile of unintentional drug overdoses.
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deaths in the United States between
1999 and 2005,81 and a 129.2%
increase in deaths from prescription
opioids, between 1999 and
2002.80
Mortality Rates
Relevant studies that reported
either population-based mortality
rates attributable to fatal drug
overdose, or all-cause and
cause-specific death rates among
drug users, are presented in Table
3, organized by type of drug,
location and time period, and
sample. Rates are crude and
overdose-related, unless otherwise
noted in the table. Rates are re-
ported as number of deaths per
100 000 person-years; we con-
verted original rates from articles
that were presented on a different
scale accordingly. Mortality rates
differed widely depending on the
setting and on the source popula-
tion (i.e., any substance users, in-
jection drug users only, recently
released prisoners).
Population-based crude overdose
mortality rates (n=30 samples from
22 articles) ranged from0.04 to 46.6
per 100000 person-years.5,7,22,41,
71,73,76,81,82,84,92,95,107,109---111,121---
123,125---127 This range is likely at-
tributable to the diversity in re-
gions, time periods, and samples.
The highest rates were generally
seen in cities such as Barcelona,
Spain,111 and Chicago among
high-poverty communities,95 or in
very rural areas such as West
Virginia125 and Wilkes County,
North Carolina,127 the latter of
which was before an intervention.
Population-based adjusted or
standardized rates (n = 35 sam-
ples from 12 articles) ranged
from 0.11 to 253.8,2,78,79,
92,96,102,103,105,108,111,132,134 the
highest rate being that of Van-
couver, British Columbia, before
the opening of the first medically
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Several studies reported on over-
dose mortality rates stratified by
gender. Female-specific population-
based overdose mortality rates
reported included 9.8 in the
United States, 0.94 in England
and Wales, 0.7 in Italy, and 590
among recently released female
prisoners.6,106,131,133 Male rates
were 3.7 in England and Wales,
6.6 in Italy, and 520 among
recently released male pris-
oners.106,131,133 Generally, death
rates were higher among men
than women, with the exception
of recently released prisoners.
Among samples that included
only drug users, overdose mor-
tality rates were as high as
451.8,115---117 and all-cause mor-
tality rates ranged from 277 to
1368.56,114,118 Among treatment-
based samples, rates of drug-
related deaths ranged from 309
to 2100.41,104,124,128---130 Among
samples of HIV-positive individuals,
overdose death rates were 1120 to
1390.119,120
Correlates
Type of drug. Substances most
commonly associated with over-
dose include cocaine, nonopioid
analgesics (i.e., nonsteroidal anti-
inflammatory drugs), and opioids—
a class of drug that includes her-
oin, as well as prescription opioids
such as morphine, methadone,
codeine, and oxycodone. Some
findings on how class of drug used
affects overdose outcome are
highlighted here.
Cocaine was one of the major
drivers of overdose in the 1990s
and early 2000s, especially in
urban areas such as New York
City.22,23 In a study of witnessed
overdoses in New York City in the
early 2000s, powdered cocaine
use predicted fatality among re-
spondents’ reported last witnessed
overdose.17 However, a shift
toward opioids has occurred
worldwide throughout the past
several years.135
In a study of fatal overdoses in
Connecticut, 77% of accidental
overdose deaths from 1997 to
2007 involved opioids.90 Opioid
deaths were also more likely to
involve alcohol and benzodiaze-
pines.2,85,90 Several articles
focused on fentanyl, an opioid
receptor agonist that is used as
a filler for street heroin (or laced
into heroin and cocaine) and has
been more frequently prescribed
in recent years.136,137 Fentanyl is
estimated to be 80 times more
potent than morphine, so a small
change in dosage may be fatal.
Compounding this issue, many
narcotic drug screens do not rou-
tinely screen for fentanyl.138 Only
1 of the studies that included
prescription medications69 dif-
ferentiated between those who
experienced overdoses secondary
to nonmedical use (i.e., using in
larger amounts than prescribed or
not prescribed for them) and had
been prescribed these drugs ver-
sus those who experienced
overdoses but had never been
prescribed these drugs. Of the 596
respondents included in this study,
72.8% had already been pre-
scribed in their lifetime prescrip-
tion opioids, 45.5% had already
been prescribed prescription tran-
quilizers, and 45.1% had already
been prescribed prescription
stimulants. None of the mortality
articles included in our review had
information on whether those who
died because of overdoses sec-
ondary to prescription drug use
had been using these drugs for
therapeutic purposes.
Whether drugs are taken in
pure form on their own or com-
bination form (including mixed
with alcohol) is important.16,77
“Polydrug” use is associated with
a much higher risk of death from
overdose; a study of opioid
overdoses presenting to an emer-
gency department in Switzerland
found that up to 90% of patients
tested positive for multiple
drugs.139 According to the New
York City Department of Health
and Mental Hygiene, about 98%
of overdose deaths that occur in
the city involve more than 1 sub-
stance.140 In addition, a review of
Australian national coroner’s re-
cords from 2000 to 2007 found
that 72% of drug-related deaths in
released prisoners involved poly-
drug use.141
For studies based on interviews
about personal overdose experi-
ences or witnessed overdoses, we
cannot know with certainty ex-
actly what type of drug or how
many the person overdosed on,
but rely on participant responses
(e.g., Tracy et al.16). These types of
studies also often have inclusion
criteria such as had to have in-
jected heroin within the past 2
months15 or had to have injected
heroin or cocaine during the pre-
ceding 30 days,37 which give us
some indication of what drug was
likely used, but it is not always
specified. Some were treatment
samples of specific types of drug
users41,43 in which we generally
assume for simplicity that if they
were heroin injectors, they over-
dosed on heroin. Some studies do
specify “heroin only,” for example,
or differentiate between “heroin
only” and “heroin and other
drugs,”49 though, again, these are
often based on self-report. Others
still differentiate between single
drugs and combination, but are
based on autopsy findings or a mix
of autopsy findings and circum-
stances of the fatality that we can
be a little more sure about.113 Most
of the larger countrywide studies
on mortality or trends look at
overall deaths or hospitalizations,
not distinguishing between type of
drug (e.g., White et al.11).
Setting or regional differences.
Drug overdose is not just an urban
problem, even though historically
more emphasis has been placed
on urban areas.142---144 In recent
years, rural areas have seen rapid
increases in rates of nonmedical
prescription drug use and over-
dose: in rural Virginia between
1997 and 2003, fatalities attrib-
uted to overdose increased by
300% (prescription opioids and
benzodiazepines were more prev-
alent than illicit drugs).76 In Utah,
prescription opioid deaths in-
creased fivefold during 2000 to
2009.28 Furthermore, prescrip-
tion drug overdose is now the
leading cause of injury death in
Ohio, with particularly high rates
in the rural Appalachian areas of
the state.84
In addition, the setting and cir-
cumstances of a drug overdose
can tell us a lot about potential
outcomes. In a study of fatal
overdose in New York City in
1996, deaths were more likely to
occur in neighborhoods in the top
decile of income inequality than in
more equitable neighborhoods.145
This relationship was partially
explained by the level of disorder
in the environment and the quality
of the built environment. When
compared with nonoverdose but
unintentional deaths, prescription
opioid overdose deaths from an-
other study in New York City were
more likely to occur in lower-
income and “fragmented” neigh-
borhoods, but when compared
with heroin fatalities, they were
more likely to occur in higher-
income and less-fragmented
neighborhoods.146 One explana-
tion for this is that higher-income
neighborhoods offer a larger sup-
ply of prescription opioids through
pharmacies and physicians that is
not present in more disadvan-
taged, primarily minority neigh-
borhoods. A study in 10 Spanish
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cities from 1996 to 2003 found
that male overdose deaths were
more common in cities with
high levels of socioeconomic
inequality.147
The physical settings in which
users inject also matter. A Van-
couver study estimated that users
who injected in public places (vs
those who injected in private set-
tings) were 4.7 times more likely
to experience a nonfatal over-
dose.19 A study by Bohnert et al.
on policing and risk of overdose in
New York City found that fatal
overdoses were more likely to
occur in secluded public places,
such as abandoned buildings.20
This is likely attributable to the
fact that it is more difficult to find
help when someone overdoses,
and may be a result of fear of
heavy policing in urban areas.
Another study that investigated
risks of heroin overdose noted
injection in an “unusual place”
(defined by each individual
according to his or her injecting
habits) as a risk factor for over-
doses.21 One explanation pre-
sented for this phenomenon is that
tolerance is based on Pavlovian
conditioning of cues, and when
a user of typically high tolerance
injects in an unusual circumstance,
they lack the cues that they usually
associate with a drug’s effect,
causing their tolerance to fail.148
Characteristics of the user. Lastly,
characteristics of the drug user are
important to consider as correlates
for drug overdose. One character-
istic of note is gender. Men are
more likely to self-report non-
medical use of prescription drugs,
yet more women are more often
prescribed drugs prone to
abuse.149,150 This might be
because of the fact that many
common forms of pain such as
osteoarthritis, fibromyalgia,
lower-back pain, and shoulder
pain are more prevalent among
women, and women also report
higher intensity of pain from these
conditions.151,152 The US Centers
for Disease Control and Preven-
tion reported that the proportion
of drug overdose deaths caused by
prescription opioids was highest
among women aged 45 to 54
years and among American Indian
or Alaska Natives and non-
Hispanic White women.153 A
study in Australia showed a 70-to-
30 male-to-female ratio of non-
fatal heroin overdose.142
Another commonly studied
correlate is race/ethnicity. A re-
view of coroner case files from
British Columbia from 2001 to
2005 found that First Nations in-
dividuals had higher rates of
mortality from overdose.108 An
investigation of fatal accidental
drug overdose in New York City
between 1990 and 1998 found
that overdose deaths were consis-
tently higher among non-Hispanic
Blacks and Hispanics compared
with non-Hispanic Whites. In ad-
dition, cocaine was more common
among non-Hispanic Black dece-
dents, whereas opioids and alco-
hol were more common among
Hispanic and non-Hispanic White
decedents.22 On the other hand,
rates of prescription opioid deaths
are higher among non-Hispanic
Whites than among respondents
of other races/ethnicities.153
Other factors associated with
increased risk of nonfatal over-
dose found in the literature review
included belonging to a lower in-
come group while growing up, not
graduating high school, being
a smoker, having ever received
care at a psychiatric facility, ever
witnessing a family member over-
dose, being prescribed tranquil-
izers, having cocaine dependence,
and injecting in the past 90
days.28,36,69,154
Certain subgroups of the popu-
lation are especially prone to
overdose risk, including homeless
individuals, HIV-positive individ-
uals, and recently released pris-
oners.65,120,155,156 Individuals who
have recently attended substance
abuse treatment or been released
from incarceration are at increased
risk of overdose, often because they
have lost tolerance for their usual
doses.26,157 Overdose is also signif-
icantly associated with psychiatric
disorders, suicidal ideation, and
attempted suicide.67,158 Lastly, du-
ration of drug use and reports of




the peer-reviewed literature to
document the global epidemio-
logical profile of unintentional
drug overdoses, and the preva-
lence, time trends, mortality rates,
and correlates of drug overdoses.
We found, first, wide variability in
the lifetime prevalence of experi-
encing a nonfatal overdose and in
mortality rates attributable to
overdoses, depending on the study
setting. Second, the majority of
studies on longitudinal trends
of overdose death rates or
overdose-related hospitalization
rates showed increases in
overdose death rates and in
overdose-related hospitalization
rates across time, which have led
to peaks in these rates now. In
particular, an overall trend of in-
creasing deaths from prescription
opioid use and decreasing deaths
from illicit drug use in the past
several years has been noted
across most of the literature.80---
82,89,90,96,97,99,100 Third, with the
increase in prescription opioid
overdose deaths, drug overdose is
no longer just an urban problem:
rural areas have seen an important
increase in overdose deaths.
Fourth, cocaine, prescription
opioids, and heroin are the drugs
most commonly associated with
unintentional drug overdoses
worldwide and the demographic
and psychiatric correlates associ-
ated with unintentional drug
overdoses are similar worldwide.
However, more studies examining
these correlates are needed from
non---English-speaking countries.
Drug overdose is an important,
yet inadequately understood, public
health problem. A review of existing
studies points to several key meth-
odological issues that future studies
need to address and limitations in
extant studies. Methodological is-
sues include enhancing data collec-
tion methods on unintentional fatal
and nonfatal overdoses, and col-
lecting more detailed information
on drug use history, source of drug
use (for prescription drugs), and
demographic and psychiatric his-
tory characteristics of the individual
who overdosed. For example, fu-
ture studies could employ consis-
tency check strategies to compare
medical examiner information on
fatal overdoses with available med-
ical records and information from
the deceased individuals’ family
members.
Future data collection efforts
could also include more detailed
questions when interviewing indi-
viduals who report nonfatal over-
doses, and check consistency of
such information with hospital
discharge data and information
from family or other third parties
(e.g., friends who witnessed the
overdose episode). The field still
also lacks studies in rural areas as
well as longitudinal studies of
population-based drug users
(i.e., non---treatment samples) in
multiple urban and rural areas
that would provide us with com-
parable prevalence estimates
across different contexts.
In addition, several of the se-
lected studies did not disclose how
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they defined nonfatal overdoses to
study respondents,33,34,37 simply
mentioning that they asked them if
they had ever experienced or wit-
nessed an overdose, which could be
somewhat misleading and biased.
On the other hand, it should be
noted that, among the studies that
provided information on the defi-
nition of nonfatal overdoses, the
definition of nonfatal overdoses was
overall extremely consistent and
standardized across the reviewed
studies, similar to the definition we
present in the introduction of this
review.12,14--17,36,39,40
The marked increase in pre-
scription opioid overdoses de-
scribed in the studies reviewed is
likely attributable to a rapid in-
crease in sales of prescription opi-
oids during the past decade; the
quantity of prescription opioids
sold to pharmacies, hospitals, and
doctors’ offices in the United
States was 4 times larger in 2010
than in 1999.8 The increase in
overdoses caused by prescription
opioid use in the United States
parallels the increase in the avail-
ability of prescription opioids
since the early to mid-1990s in
the United States.90 As described
in one of Nora Volkow’s recent
presentations to the US Senate:
The number of prescriptions
for opioids (like hydrocodone
and oxycodone products)
have escalated from around
76 million in 1991 to nearly
207 million in 2013, with
the United States their biggest
consumer globally, accounting
for almost 100 percent
of the world total for hydro-
codone (i.e., Vicodin) and 81
percent for oxycodone
(i.e., Percocet).161(p3)
There is a need to invest in
research to understand the distinct
determinants of this type of over-
dose worldwide. Several other
countries need to collect in a sys-
tematic and continuous fashion
such data on sales of prescription
opioids and other prescription
drugs, nonmedical use of prescrip-
tion drugs, and hospitalization sec-
ondary to overdoses on prescription
drugs. Moreover, there is the need
for future studies to further investi-
gate whether those who overdose
while using prescription medication
had been prescribed these drugs
recently or in the past because only
1 of the reviewed studies included
this information.69
Finally, the sparse evidence on
the environmental determinants
of overdose suggest a need for
research that will inform the types
of environmental interventions we
can use to prevent drug overdose.
A combination of studies on in-
dividuals who overdose and the
settings where overdoses occur
will help us better tailor interven-
tions to the types of strategies that
are most likely to have a major
impact on this epidemic.
Limitations of the reviewed
studies are also noted. First, most
studies did not collect information
on the sources of drug used, which
can provide insights into the ways
individuals learn about and ac-
quire drugs, and can thus inform
prevention opportunities. Drugs
can be acquired from family,
friends, and drug dealers, but they
can also be prescribed for legiti-
mate medical reasons (in the case
of prescription drugs). More stud-
ies that investigate prescribing
patterns, such as the article by
Logan et al. on potentially inap-
propriate prescriptions given in
the emergency department,162 are
needed. Moreover, only about
a third of the mortality rate stud-
ies, half of trends studies, and one
sixth of the prevalence studies
stratify results by specific types of
prescription drugs.
Second, it is already well estab-
lished that there might be an
underreporting of intentional
overdoses, because when
substance users are asked whether
their overdose was or was not
intentional, most report it as un-
intentional.29,163,164 In our review,
we focused on unintentional
overdoses, but there is the possi-
bility that some of these overdoses
were truly intentional.
Third, because substance users
who experience an overdose are
usually polydrug users, it is very
difficult to distinguish which and
how many drugs were used before
an overdose episode.165---168 Be-
cause of the high prevalence of
multiple drugs being present in
overdoses,11,139 it is hard to tease
out the effect of one drug over
another. Overall, there is a mix of
how well studies differentiate, but
many aim to show an overall
measure of burden of this issue,
not truly trying to make a causal
association with any 1 type of
drug.
Fourth, studies have shown that
forensic toxicology laboratories
are limited in the number of drugs
for which they can screen and that
drug levels can change postmor-
tem.165---168 Further complicating
this issue is the fact that data
collected by medical examiners
and coroners are usually inade-
quate, incomplete, and inconsis-
tent with regard to polydrug use,
estimated drug dosage (when, for
instance, the individual had a le-
gitimate prescription for at least 1
of the drugs involved in the fatal
overdose episode—e.g., a legiti-
mate opioid prescription), and pa-
tient characteristics.169
Fifth, if we are to identify po-
tential avenues to prevent drug
overdose, more concerted invest-
ment needs to be made to un-
derstand the environmental
drivers of overdose risk, and the
individual and interpersonal
mechanisms whereby environ-
mental characteristics can increase
the risk for overdose. This is
particularly important for over-
dose risk in rural areas, as the bulk
of the literature on environmental
determinants of overdose has fo-
cused on urban areas. This also
has important implications for
prevention and intervention strat-
egies that need to focus on harm
reduction strategies such as the
availability of safe injection facili-
ties or mobile safe injection facili-
ties where individuals can inject
preobtained drugs under the su-
pervision of a medical doctor, such
as facilities that exist in Canada
and in some European countries,19
while also offering them treatment
for their drug-using behavior. j
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